Bodyport

Founded in 2014 by Corey Centen and Sarah Smith, San Francisco-based Bodyport is a digital therapeutics company developing FDA-cleared remote monitoring devices for heart failure management. The company's flagship product, the Fluiditi smart scale, non-invasively measures cardiac biomarkers and fluid status in approximately 20 seconds to detect early signs of heart disease and prevent hospitalizations. Recent clinical data demonstrates that this platform provides a median 14-day advance warning for heart failure events while generating 38% fewer false alerts compared to standard weight-based monitoring. Operating with fewer than 25 employees and generating under $5 million in annual revenue, the enterprise has raised $13.82 million in total venture capital funding to date. This financing includes an $11.2 million Series A round backed by the Boehringer Ingelheim Venture Fund, an investment which placed Stefan Pflanz on the corporate board.

High-Level Overview

Bodyport is a health technology company focused on predicting and preventing heart disease, primarily targeting heart failure—a chronic condition affecting over 6 million Americans and causing approximately 1 million hospitalizations annually. The company’s core product is the Bodyport Cardiac Scale, a novel, noninvasive weight scale embedded with cardiovascular sensors that measure cardiac output, congestion, heart rate, and other key indicators of heart health during a patient’s daily weigh-in. This data is analyzed by proprietary predictive algorithms and software, enabling care teams to remotely monitor patients, identify early signs of cardiac deterioration, and optimize therapies to prevent hospitalizations and reduce healthcare costs. Bodyport serves patients with chronic heart conditions and healthcare providers managing these populations, aiming to improve patient outcomes through seamless integration into daily routines and actionable clinical insights[1][2][4][5].

Origin Story

Founded in 2015 by biomedical engineers Corey Centen and Sarah Smith, Bodyport emerged from their expertise in cardiovascular technology and a vision to empower people to live free from complex chronic conditions. The idea originated from recognizing the limitations of existing cardiac monitoring technologies, which were often invasive, costly, or required high patient engagement. Bodyport’s founders developed the Cardiac Scale to transform cardiac monitoring into a simple, daily step that fits naturally into patients’ lives. Early traction included FDA 510(k) clearance in August 2022 and adoption by multiple hospitals, validating the technology’s clinical utility and potential to shift care from reactive to predictive[1][4][6][9].

Core Differentiators

• Product Differentiators: The Bodyport Cardiac Scale uniquely combines multiple cardiovascular biomarkers (cardiac output, fluid congestion, heart rate) in a single, noninvasive device that patients use daily at home, unlike competitors focused mainly on ECG or wearable devices[2][7].
• Developer Experience: Designed by seasoned biomedical engineers with deep cardiovascular expertise, the product emphasizes ease of use, requiring only about 20 seconds per day, seamlessly integrating into patient routines[6].
• Speed, Pricing, Ease of Use: The scale provides rapid, comprehensive cardiac assessments without invasive procedures or complex workflows, improving patient adherence and engagement[3][6].
• Community Ecosystem: Bodyport supports care teams with predictive analytics and clinical dashboards, enabling proactive, personalized interventions and reducing false alerts by 38% compared to traditional weight-based monitoring[7][8].

Role in the Broader Tech Landscape

Bodyport rides the growing trend of remote patient monitoring and digital therapeutics in cardiovascular care, addressing the urgent need to reduce hospitalizations and healthcare costs associated with chronic heart failure. The timing is critical as healthcare systems increasingly adopt telemedicine and value-based care models that emphasize prevention and early intervention. Market forces such as rising chronic disease prevalence, advances in sensor technology, and regulatory support (e.g., FDA clearance) favor Bodyport’s solution. By providing actionable, longitudinal cardiac data in a familiar form factor, Bodyport influences the ecosystem by enabling scalable, patient-centered care pathways and setting new standards for remote cardiac monitoring[2][4][5][7].

Quick Take & Future Outlook

Looking ahead, Bodyport is positioned to expand beyond heart failure into other chronic conditions like hypertension, diabetes, and COPD, leveraging its platform’s versatility. Trends shaping its journey include increasing adoption of digital health tools, integration with broader healthcare IT systems, and growing emphasis on predictive analytics in chronic disease management. As Bodyport scales its commercial partnerships and clinical evidence base, its influence may evolve from a niche cardiac monitoring device to a cornerstone of chronic disease management, helping shift healthcare from reactive to proactive care. This aligns with its mission to empower individuals to live healthier lives through simple, actionable insights derived from everyday health signals[3][5][6].